Recent research have converged on the overlap of GLP|GIP|GCGR stimulant therapies and dopamine signaling. While GIP activators are widely employed for treating type 2 T2DM, their potential consequences on motivation circuits, specifically governed by DA systems, are gaining considerable interest. This paper details a concise assessment of current p